Literature DB >> 11258604

Acute changes in plasma levels of hepatocyte growth factor during low-density lipoprotein apheresis.

S Kojima1, M Shida, K Tanaka, H Takano, H Yokoyama, M Kuramochi.   

Abstract

Hepatocyte growth factor (HGF) is a mesenchyme-derived pleiotropic factor, and angiogenesis is included in a variety of its functional effects. HGF levels were measured in 5 sessions of low-density lipoprotein (LDL) apheresis in 3 patients with severe hypercholesterolemia. Blood was collected at the start (T0) and at 1,000 ml (T1), 2,000 ml (T2), and 3,000 ml (T3) plasma treatments. During LDL apheresis, HGF levels increased from 1.59 +/- 0.78 (mean +/- SE, n = 5) ng/ml at T0 to 6.64 +/- 0.97 at T1, 6.28 +/- 0.97 at T2, and 5.20 +/- 0.94 at T3. In one apheresis session, HGF increased immediately at the 100 ml plasma treatment stage. HGF was adsorbed completely by a dextran-sulfate (DS) column. Despite the adsorption by the DS column, HGF in the patient blood increased to the levels with functional effects. The improvement of ischemic symptoms due to LDL apheresis may be related to the angiogenic activities of HGF.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11258604     DOI: 10.1046/j.1526-0968.2001.005001002.x

Source DB:  PubMed          Journal:  Ther Apher        ISSN: 1091-6660


  3 in total

1.  Efficacy of low-density lipoprotein apheresis combined with corticosteroids for cholesterol crystal embolism.

Authors:  Katsuya Ishiyama; Toshinobu Sato; Takuhiro Yamaguchi; Yoshio Taguma
Journal:  Clin Exp Nephrol       Date:  2016-04-21       Impact factor: 2.801

2.  Hybrid revascularization for critical limb ischemia triggered by multiple organ dysfunction due to acute pneumonia; urgent catheter intervention followed by low-density-lipoprotein apheresis and elective peripheral bypass surgery.

Authors:  Yoshitaka Hayashi; Kazumi Mizuguchi; Katsutoshi Takayama
Journal:  Ann Vasc Dis       Date:  2014-05-16

Review 3.  Applications of LDL-apheresis in nephrology.

Authors:  Shuzo Kobayashi
Journal:  Clin Exp Nephrol       Date:  2008-01-05       Impact factor: 2.801

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.